Bio Medica Laboratories (NSE:BMLL) Short-Term Debt: ₹82.5 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BMLL Bio Medica Laboratories Ltd NSE:BMLL
18 GF Score
Price ₹146.80
! 7 Warning Signs
View Full Analysis

What is Bio Medica Laboratories Short-Term Debt?

Bio Medica Laboratories NSE:BMLL +1.21% 18 Short-Term Debt is ₹82.5 Mil as of Mar. 2025. GuruFocus rates NSE:BMLL with a GF Score™ of 18/100. The stock has 7 warning signs investors should review.

Bio Medica Laboratories's Short-Term Debt for the quarter that ended in Mar. 2025 was ₹82.5 Mil.

Bio Medica Laboratories's quarterly Short-Term Debt declined from Mar. 2023 (₹49.4 Mil) to Mar. 2024 (₹27.2 Mil) but then increased from Mar. 2024 (₹27.2 Mil) to Mar. 2025 (₹82.5 Mil).

Bio Medica Laboratories's annual Short-Term Debt declined from Mar. 2023 (₹49.4 Mil) to Mar. 2024 (₹27.2 Mil) but then increased from Mar. 2024 (₹27.2 Mil) to Mar. 2025 (₹82.5 Mil).

Bio Medica Laboratories Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Bio Medica Laboratories Short-Term Debt Related Terms

Bio Medica Laboratories Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Bio Medica Laboratories's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio Medica Laboratories Short-Term Debt Chart

Bio Medica Laboratories Annual Data
Trend Mar23 Mar24 Mar25
Short-Term Debt
49.36 27.24 82.50

Bio Medica Laboratories Semi-Annual Data
Mar23 Mar24 Mar25
Short-Term Debt 49.36 27.24 82.50
NSE:BMLL
18GF Score
Bio Medica Laboratories Ltd NSE:BMLL
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₹82.5 Mil mean?
Bio Medica Laboratories (NSE:BMLL) has a Short-Term Debt of ₹82.5 Mil as of Mar. 2025.
Is Bio Medica Laboratories' Short-Term Debt too high?
Bio Medica Laboratories' current Short-Term Debt is ₹82.5 Mil. Overall, Bio Medica Laboratories has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' Short-Term Debt compare to ISRG and BDX?
Bio Medica Laboratories' Short-Term Debt of ₹82.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Bio Medica Laboratories's current Short-Term Debt is ₹82.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current Short-Term Debt of ₹82.5 Mil. The current Short-Term Debt is ₹82.5 Mil. Bio Medica Laboratories' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current Short-Term Debt is ₹82.5 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio Medica Laboratories Business Description

Address Sanwer Road, Plot No. 11B-11C, Sector-E, Industrial Area, Industrial Estate - Indore, Indore, MP, IND, 452015
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
18GF Score

Get the complete analysis for NSE:BMLL

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹146.80
Price